Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial.

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart (2008) 1.07

Clinical and economic studies of eptifibatide in coronary stenting. Ther Clin Risk Manag (2014) 0.81

Eptifibatide: The evidence for its role in the management of acute coronary syndromes. Core Evid (2010) 0.80

Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction. Scientifica (Cairo) (2012) 0.77

Impact of Timing of Eptifibatide Administration on Preprocedural Infarct-Related Artery Patency in Acute STEMI Patients Undergoing Primary PCI. Int J Angiol (2014) 0.75

Effect of Early Treatment With Tirofiban on Initial TIMI Grade 3 Flow of Patients With ST Elevation Myocardial Infarction. Iran Red Crescent Med J (2014) 0.75

Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions. Curr Cardiol Rev (2012) 0.75

Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34

Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90

Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47

Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69

Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med (1985) 7.29

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (2009) 6.19

Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86

A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA (2013) 4.85

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet (2008) 4.71

A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheter Cardiovasc Interv (2013) 4.64

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol (2002) 4.64

A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53

Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med (2005) 4.13

Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10

Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02

ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation (2002) 3.80

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79

The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (2013) 3.74

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56

Race and gender differences in C-reactive protein levels. J Am Coll Cardiol (2005) 3.51

State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation (2008) 3.25

Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol (2005) 3.20

Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA (2008) 3.12

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J (2008) 3.02

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA (2005) 2.93

Triage of patients with acute chest pain and possible cardiac ischemia: the elusive search for diagnostic perfection. Ann Intern Med (2003) 2.92

Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J (2008) 2.92

Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation (2002) 2.86

Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ (2006) 2.85

The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 2.79

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2010) 2.76

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2008) 2.75

Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA (2002) 2.75

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72

Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72

Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation (2003) 2.70

Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ (2012) 2.66

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2007) 2.64

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2005) 2.62